Clinical Trials Logo

Filter by:
NCT ID: NCT02362776 Completed - Breast Cancer Clinical Trials

Metabolic Changes as a Diagnostic Indicator for Cancer

Start date: October 2009
Phase: N/A
Study type: Observational [Patient Registry]

This study aims to determine whether metabolic changes occur in blood plasma of cancer patients, and whether these changes can be used as a biomarker to detect cancer. These analyses will be done by means of nuclear magnetic resonance (NMR) spectroscopy.

NCT ID: NCT02362516 Completed - Healthy Clinical Trials

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Start date: February 2015
Phase: Phase 1
Study type: Interventional

To assess the exposure of BI 425809 in cerebrospinal fluid relative to plasma as well as safety and tolerability, and to evaluate the effect of different doses of BI 425809 on biomarkers levels in cerebrospinal fluid.

NCT ID: NCT02360540 Completed - Pulmonary Embolism Clinical Trials

PERCEPIC: PERC Rule Combined With Implicit Low Clinical Probability

PERCEPIC
Start date: May 2015
Phase: N/A
Study type: Observational [Patient Registry]

PERC rule was created to rule out pulmonary embolism (PE) without further exams, with residual PE risk <2%. Its safety is currently confirmed in low PE prevalence populations as north-American. In European high PE prevalence population, it has been showed that PERC rule used alone or associated with low clinical probability assessed by revised Geneva score (RGS) was not safe. In retrospective study, we suggest that the combination of PERC rule with implicit clinical probability (gestalt) could allow the use of the PERC rule. PERCEPIC, an observational prospective multicenter study performed in France and Belgium, will test this hypothesis. Therefore, 3000 patients will be included in 12 centers. Primary outcome will be the rate of thromboembolic events or death related or possibly related to PE in patients with low implicit clinical probability and negative PERC rule (8 criteria absents). Upper limit of confidence interval of this rate must be equal or lower than 3% to consider PERC rule as safe in this combination.

NCT ID: NCT02359578 Completed - Clinical trials for Determination of the Occlusion Pressure in Lymphatic Vessels

Determining Occlusion Pressure in Lymphatic Vessels

Occlusion
Start date: August 2014
Phase: Phase 0
Study type: Interventional

The lymphatic system is one of the keystones of fluid homeostasis in the interstitium. In analogy with the arterial systolic pressure, the lymphatic systolic pressure can give us information about the functioning of the cardiovascular system and fluid exchange. Actually, knowledge about this physiological parameter is incomplete because of the lack of technology. Former measurement techniques of the lymphatic systolic pressure in the living healthy man were invasive and too complex to be interpreted. The lymphatic occlusion pressure has to be clarified because lymphedema treatment, concerning the pressure to be applied on the edematous tissue is still based on controversial concepts. On one hand, techniques such as Manual Lymphatic Drainage, sustain the necessity to apply a very low pressure in order to avoid the squeezing of superficial lymph vessels. On the other hand sustainers of Intermittent Compression Therapy advocate the necessity to apply relatively high pressure to obtain a decongesting effect. These completely opposite opinions triggered us to study lymphatic pressure more thoroughly. Lymphofluoroscopy (emerging imaging technique in the field of lymphology) is now used since 3 years by the promoters of this study to visualize the architecture of the superficial lymphatic network and the progression of the lymph inside the highlighted vessels. This technique will be used in the present (prospective and multicentric) study to observe the effect of a pressure applied on the limb on the displacement of the lymph, and then to determine the occlusion pressure of the lymphatic vessels.

NCT ID: NCT02359292 Completed - Asthma Clinical Trials

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Start date: February 2015
Phase: Phase 1
Study type: Interventional

The study is performed to evaluate the total systemic exposure and lung bioavailability of CHF 5993 pMDI combination, in healthy volunteers subjects.

NCT ID: NCT02357420 Completed - Diabetes Mellitus Clinical Trials

Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Start date: January 29, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1 and Type 2 diabetes mellitus and gastroparesis. Study drug (relamorelin and placebo) will be administered subcutaneously in a blinded fashion.

NCT ID: NCT02356029 Completed - Clinical trials for Cardiopulmonary Arrest

Perception of Inappropriate CPR: a Multicenter International Cross-sectional Survey

REAppropriate
Start date: March 2015
Phase:
Study type: Observational

The primary objective of this study is to determine how often cardiopulmonary resuscitation (CPR) is perceived as inappropriate by Healthcare Providers (HCPs) working in prehospital Ambulance Services and Emergency Departments. Perception of inappropriate CPR is defined as resuscitation efforts perceived by HCPs as disproportionate to the expected prognosis of the patient in terms of survival or quality of life. When a HCP perceives CPR as inappropriate, this may cause moral and emotional distress. This perception may be modulated by the personal background and professional role of the HCP, but also by his/her working conditions. Apart from the workload, the resulting distress can be influenced by the way non-technical skills are developed within the team and the ethical environment in which the HCP functions. Frequent exposure to similar patient care situations and/or a professional environment not acknowledging the distress may lead to deficient coping mechanisms and accumulation of moral distress. This may be associated with job leave, burnout and a decreased quality of patient care. Acute distress may also influence the quality of care provided to actual and future patients. Secondary objectives of the study are to evaluate whether perceived inappropriateness of CPR is not only associated with patient related factors but also with personal characteristics and work related factors. Potential consequences for HCP's like moral distress and intentional job leave will be assessed.

NCT ID: NCT02355756 Completed - Healthy Volunteers Clinical Trials

Biomarker Development for Future PAC1 Antagonists With Maxadilan

Start date: January 2015
Phase: Phase 0
Study type: Interventional

This will be a single center, open-label study in healthy male subjects between 18 and 45 years old to determine the dose response profiles of dermal blood flow in response to intradermal injections of maxadilan. The study will consist of 2 parts: Part I: dose and time finding and Part II: reproducibility over time.

NCT ID: NCT02355561 Completed - Healthy Clinical Trials

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Start date: January 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the effect of a high-fat/high-caloric breakfast on the rate and extent of absorption of the single oral dose of 25 mg JNJ-54861911 test formulation in healthy elderly participants.

NCT ID: NCT02355106 Completed - Atrial Flutter Clinical Trials

Prospective, Multicenter, Investigation of the Adagio Cryoablation System in Subjects With Atrial Flutter

Start date: January 2015
Phase: N/A
Study type: Interventional

The objective of the study is to demonstrate the safety and feasibility of the Adagio System in subjects with Atrial Flutter.